Home > Back to Publisher > Report Information

China Pharmaceutical Regulatory Report 2010 + Appendix

Pacific Bridge Medical
January 1, 2010
70/125 app Pages - SKU: PACB2621522

Abstract Table of Contents Related Reports

Countries covered: China

This report includes a brief overview of the pharmaceutical and healthcare industry in China, as well as a discussion of all the relevant laws and regulations that govern the testing, registration, manufacture, import, marketing, and sale of pharmaceutical products. Specific topics include: product registration, pricing and reimbursement, importation, GMP, GCP, orphan drugs, and intellectual property protection.

This report's appendix contains a full translation of the revised Administrative Provisions for Drug Registration, the recent overhaul of China's drug regulations. It also contains the annexes to this document detailing dossier submission requirements, all up-to-date.

Fully updated for 2010!

Completely new information has been added to this report, including distribution in Section I, the 2009 Health Care Reform in Section II, new regulatory changes in Section III, drug purchasing system in Section VII, and drug safety in Section VIII. There are also updates on drug registration statistics, GMP, re-registration processes, and packing requirements. The appendix has also been updated, such as CRO information and SFDA affiliate organizations.

I. China Pharmaceutical Industry Overview: A. Overview; B. China Pharmaceutical Market Trends; C. China's Pharmaceutical Distribution System; D. Brief Overview of China's Pharmaceutical Regulations; E. The State Food and Drug Administration
II. The China Healthcare System: A. History of Healthcare System in China; B. Struggling Healthcare Services Sector; C. Hospitals and Medical Resources; D. Health Insurance in China; E. 2009 Health Care Reform
III. Drug Registration Regulations: A. Drug Registration Policy; B. Classification of Drugs; C. Drug Registration Application; D. Application Documents for New Drug Registration; E. Technical Review Guidance for Registration Documents; F. New Drug Registration Process; G. OTC New Drug Registration Process; H. New Drug Registration Statistics; I. Classification of Combination Drug-Device Products; J. New Regulatory Changes
IV. Drug Pricing Regulations: A. Overview of Drug Pricing; B. Controls on Drug Pricing; C. National Essential Medical Insurance Drug List V. Pharmaceutical Research and Development and Related Regulations; A. China's Research and Development Climate; B. Clinical Research; C. Good Clinical Practice (GCP); D. GCP-Certified Clinical Research Centers; E. Good Laboratory Practice (GLP); F. Adverse Event Reporting Requirements
VI. Pharmaceutical Manufacturing Regulations: A. Manufacturing Pharmaceuticals in China; B. GMP Regulations; C. GMP Certification; D. Drug Manufacturing Administration; E. Drug Manufacturing Certificate; F. Biological Products
VII. Selling Pharmaceuticals and Related Regulations: A. WTO Agreement on Drug Sales; B. Drug Sales to Hospitals; C. Drug Purchasing System; D. Selling Drugs in Drug Stores; E. Drug Sales on the Internet; F. Distribution Regulations; G. OTC Drug Sales; H. Regulations on Drug Imports; I. Drug Recalls
VIII. Drug Safety
IX. Authorized Quality Person
X. Marketing Drugs in China: A. Packaging Requirements
XI. Drug Advertising
XII. Intellectual Property Protection: A. Current Intellectual Property Situation in China Pharmaceutical Market; B. Examples of Pharmaceutical Companies Experience with IPR infringement in China; C. Administration Protection (AP)
XIII. Conclusion APPENDICES:: A. Application Form for Drug Registration; B. Listing of CROs in China; Regulatory Specifics for Clinical Trials in China; C. Administrative Provisions for Drug Registration (translated law); D. Registration for TCM (translated law); E. Registration for Chemical Drugs (translated law); F. Registration for Biological Drugs (translated law); G. Supplemental Drug Application Registration (translated law); H. Drug Re-registration Application (translated law); I. Drug Monitoring Periods; J. Application and Approval Procedures and Timeline for Imported Drugs; K. Application and Approval Procedures and Timeline for Clinical Trials; L. Listing of SFDA-affiliated organizations in China; M. Healthcare statistics in Asia (charts)

More China Regulation & Policy Reports

China’s Guidebook for Pharmaceutical Patent Protection by Access China Management Consulting Ltd.
China’s Guidebook for Pharmaceutical Patent Protection is an essential resource for overseas and multinational pharmaceutical companies to achieve a successful patent protection for their intellectual ...

China Chinese Patent Drug Processing Industry, 2012 by Reports From China
China chinese patent drug processing industry, 2012 is valuable for anyone who wants to invest in the chinese patent drug processing industry, to get Chinese ...

China Drug Patent Inventor Report - 2011 Publication List by DrugPatentWatch
TheChina Drug Patent Inventor Reportprofiles China-based inventors leading pharmaceutical innovation. Using data on drugs approved from 2000 to 2010, this report provides complete lists of: Top ...

China Pharmaceutical Equipment Industry Report, 2011-2012 by Research in China
In recent years, Chinese pharmaceutical equipment industry has witnessed significant growth in both product quality and technological content, as well as steady rise of sales ...

Healthcare Reform in China by Business Insights
China's pharmaceutical market is growing rapidly in step with it's wider economy. The government aims to extend healthcare coverage to it's 1.3bn citizens, which will ...

See all reports like this >>

More China Reports

D&B Country RiskLine Report: China by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

Country Report China February 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Country Report China January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

D&B Country Report: China by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Wine - BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...

See all reports like this >>

China Pharmaceutical Regulatory Report 2010 + Appendix

Share this report

Other tasks

Research Assistance

Related Markets

Regulation & Policy Reports

Free Alert Me service